Serina Therapeutics is a Huntsville clinical-stage company whose public-market residual claim now sits on a single Parkinson injection rather than on a diversified pipeline. The lead candidate attaches a well-known dopamine agonist to a proprietary polymer so that a subcutaneous shot can mimic the continuous stimulation that today requires pumps and surgery. In early September an independent safety committee cleared the first patient cohort and the company described a pharmacokinetic shape consistent with sustained exposure plus blinded motor-function color in individual patients. That is formulation validation at the lowest dose, not yet a registrational result.
The equity still trades as a going-concern micro-cap even after the March private placement rebuilt the cash pile. Mid-year cash sat at $23 million. First-half operating burn already consumed more than $11 million. Management itself states existing cash does not cover the twelve months after the statements were issued. The market is therefore paying a thin premium over cash for an unproven dose-escalation and a platform that has one non-exclusive Pfizer lipid-nanoparticle license and no product revenue.
The next test is whether remaining single-ascending-dose cohorts keep the pharmacokinetic story and the injection-site profile clean enough to support the abbreviated new-drug pathway into next year. A messy safety review or another excipient-style hold would collapse the option value back toward cash, while a clean escalation would force the market to price a real Parkinson asset against the Roth equity line that now sits over the share count. The investment question is whether the clinical clock outruns the cash clock.